Urogen Pharma (NASDAQ:URGN) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Thursday.

According to Zacks, “UroGen Pharma Ltd. is a clinical stage biopharmaceutical company. It focused on developing urological pathologies with a focus on uro-oncology. The company’s product candidates include MitoGel and VesiGel which are in clinical trial stage. Its platform technologies include: RTGel and Immunotherapy. UroGen Pharma Ltd. is based in Ra’anana, Israel. “

A number of other research firms also recently issued reports on URGN. Raymond James Financial, Inc. began coverage on shares of Urogen Pharma in a report on Tuesday, May 30th. They set an “outperform” rating and a $25.00 price objective on the stock. Oppenheimer Holdings, Inc. started coverage on shares of Urogen Pharma in a report on Tuesday, May 30th. They set an “outperform” rating and a $32.00 price objective on the stock. Cowen and Company started coverage on shares of Urogen Pharma in a report on Tuesday, May 30th. They issued an “outperform” rating on the stock. Finally, Jefferies Group LLC started coverage on shares of Urogen Pharma in a report on Tuesday, May 30th. They issued a “buy” rating and a $27.00 price target on the stock. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $26.00.

Urogen Pharma (URGN) opened at 30.59 on Thursday. The company’s market capitalization is $397.95 million. The stock has a 50 day moving average of $20.20 and a 200 day moving average of $18.47. Urogen Pharma has a 12 month low of $13.01 and a 12 month high of $31.69.

COPYRIGHT VIOLATION NOTICE: This news story was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of U.S. & international copyright legislation. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/09/14/urogen-pharma-urgn-downgraded-to-sell-at-zacks-investment-research.html.

Several large investors have recently modified their holdings of URGN. Spark Investment Management LLC purchased a new position in shares of Urogen Pharma in the 2nd quarter worth about $856,000. Menora Mivtachim Holdings LTD. purchased a new position in shares of Urogen Pharma in the 2nd quarter worth about $2,331,000. LLBH Private Wealth Management LLC purchased a new position in shares of Urogen Pharma in the 2nd quarter worth about $695,000. Alps Advisors Inc. purchased a new position in shares of Urogen Pharma in the 2nd quarter worth about $195,000. Finally, Jennison Associates LLC purchased a new position in shares of Urogen Pharma in the 2nd quarter worth about $3,168,000. 36.06% of the stock is currently owned by institutional investors.

About Urogen Pharma

Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract.

Get a free copy of the Zacks research report on Urogen Pharma (URGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.